secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2022-03-25T23:59:59+00:00
Accession:  0000950170-22-004687
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Chief Development Officer Ajay Madan resigns effective April 1, 2022
------------------------------------------------------------------------------

- Ajay Madan, Ph.D., resigns as Chief Development Officer, effective April 1, 2022.
- Company expects to enter a six-month consulting agreement with Madan for transition support.
- Consulting retainer of approximately $37,346 per month.
- No replacement named; company will search for successor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/0000950170-22-004687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017022004687/crnx-20220321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer